Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement

Starting soon · Not applicable

Conditions studied: Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation, Facial Inflammatory Erythema, Dull Skin, Facial Vitality Impairment, Body Weight Management

In brief

This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement. Eligible participants will receive 5 g oral HA35 once daily on an empty stomach for 40 consecutive days. The primary objectives are to assess changes in facial and body subcutaneous fullness, inflammatory erythema, facial vitality, and body weight. Safety, gastrointestinal tolerability, and additional exploratory outcomes will be evaluated throughout the intervention period. This is a minimal-risk, oral, non-pharmacological supportive care intervention.

Key facts

Study ID: NCT07583108
Run by: Nakhia Impex LLC
People needed: 30
Starts: 2026-05-20
Expected to finish: 2026-07-20
Last updated by the study team: 2026-05-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Age 18-60 years, male or female
Seeking non-invasive improvement of facial/body appearance
Presenting with facial fullness, double chin, subcutaneous fat accumulation, facial erythema, or dull skin
Ability to complete VAS assessments and study logs
Signed written informed consent

You may not qualify if…

Aesthetic/weight loss treatments (injection, laser, liposuction, diet drugs) within 4 weeks
Significant weight change (>3 kg) within 3 months
Uncontrolled systemic disease (diabetes, hypertension, etc.)
Known hypersensitivity to hyaluronan
Pregnant or lactating women
Participation in another clinical trial within 30 days

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.